Pro, Desheng Liang has long been involved in genetic disease diagnosis, prenatal diagnosis and gene therapy research. The research and development of NIPT and NIPT-plus are widely used in non-invasive prenatal screening for chromosomal abnormalities; the establishment of cyclic single molecule amplification and weight sequencing technology (cSMART) to break through the non-invasive prenatal diagnosis of single gene diseases, which was praised as "a revolutionary breakthrough in molecular diagnosis" by international peers; a new human-derived gene targeting vector system, rDNA region targeting vector and gene editing tool TALENicase, was developed, and in situ repair treatment technology for iPSCs genes in patients with a variety of serious genetic diseases was established. At present, the team mainly carries out the following four aspects of research: Combined with rDNA targeting vector and TALENickase to carry out autologous targeted gene therapy research for severe genetic diseases such as hemophilia, DMD, SMA; using CRISPR/Cas technology to carry out gene editing research on serious genetic diseases such as hemophilia, DMD, and SMA; the rDNA region bi/multigene targeting system was used to establish disease models of genomic diseases and tumors and carry out gene therapy research; and carry out the research and development of new technologies for major genetic diseases and tumor screening based on CRISPR targeted nucleic acid detection.